Cytokinetics (CYTK) Misses Q2 EPS by 20c, misses on revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $61.70 -0.98%
EPS Growth %: +43.1%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: +43.1%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q2 EPS of ($1.34), $0.20 worse than the analyst estimate of ($1.14). Revenue for the quarter came in at $870 thousand versus the consensus estimate of $5.67 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- RxSight Inc. (RXST) PT Lowered to $5 at Stifel
- Datadog shares drop on weak Q4 revenue outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
